All In Biotech

Drug Trial Radar · NCT05691465

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer With Neuroendocrine Differentiation

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

35

Planned (sponsor's estimate)

Start

Dec 27, 2023

Primary completion

Jun 1, 2027

Study completion Jun 1, 2027

Sponsor

Sponsor type
NIH
First posted
Jan 20, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well lutetium Lu 177 dotatate works in treating patients with prostate cancer with neuroendocrine differentiation that has spread to other places in the body (metastatic). Neuroendocrine differentiation refers to cells that have traits of both hormone-producing endocrine cells and nerve cells. These cells release hormones into the blood in response to a signal from the nervous system. Hormones are biological substances that circulate through the bloodstream to control the activity of other organs or cells in the body. Lutetium Lu 177-dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177-dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Treatment with Lutetium Lu 177 dotatate may shrink the tumor in a way that can be measured in patients with metastatic prostate cancer with neuroendocrine differentiation.

Conditions

  • Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation
  • Metastatic Prostate Neuroendocrine Carcinoma
  • Metastatic Prostate Small Cell Neuroendocrine Carcinoma
  • Stage IVB Prostate Cancer AJCC v8

Interventions

  • Biospecimen CollectionProcedure

    Undergo collection of blood

  • Computed TomographyProcedure

    Undergo CT scan

  • Gallium Ga 68-DOTATATERadiation

    Given IV

  • Lutetium Lu 177 DotatateDrug

    Given IV

  • Positron Emission TomographyProcedure

    Undergo PET

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: At 6 months

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Suspended

  • Los Angeles General Medical Center

    Los Angeles, California · Recruiting

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California · Active not recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • University of Kentucky/Markey Cancer Center

    Lexington, Kentucky · Recruiting

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland · Recruiting

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina · Recruiting

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • UT Southwestern/Simmons Cancer Center-Dallas

    Dallas, Texas · Recruiting

  • UT MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center

    Madison, Wisconsin · Recruiting

  • University of Wisconsin Carbone Cancer Center - University Hospital

    Madison, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.